Skip to main content

Table 1 Characteristics of study participants at baseline and outcomes

From: Cutaneous T-cell-attracting chemokine as a novel biomarker for predicting prognosis of idiopathic pulmonary fibrosis: a prospective observational study

  Discovery cohort Validation cohort Control
Number 100 81 32
Age, years 69 (61, 75)* 72 (66, 79.5)* 61 (43, 67)
Male 86 (86)* 70 (86)* 18 (56)
Ever-smokers 91 (91)* 71 (88)* 8 (25)
%FVC 89.5 (73.7, 101.4) 79.5 (69.5, 89.2)  
%DLCO 42.7 (35.2, 53.9) 45.1 (33.4, 57.1)  
CPI 47.4 (37.3, 56.3)   
PaO2, Torr (n = 96) 82.7 (76.4, 89.1) 81.7 (73.8, 88.6)  
Six-minute walk distance, meter (n = 97) 463 (407, 520) 479.5 (421, 539)  
Lowest SpO2 during the six-minute walk test, % (n = 97) 88 (82, 92) 89 (83, 91)  
KL-6, IU/L 805 (607, 1260) 909 (595, 1600)  
SP-D, ng/mL 236.5 (132.3, 348) 206.5 (121.6, 339.3)  
LDH, IU/L 212 (193.8, 238.5) 223 (187.5, 249)  
CPFE 30 (30)   
Anti-fibrotic drug use at baseline 2 (2) 0 (0)  
Anti-fibrotic drug use more than 6 months during the observational period 51 (51) 47 (58)  
Mortality 52 (52) 19 (23)  
Observation period, months 41 (19, 68) 19 (12, 27)  
  1. Data are expressed as medians (interquartile ranges) or numbers (percentages)
  2. %FVC, the percentage of predicted forced vital capacity; %DLCO, the percentage of predicted diffusion capacity for carbon monoxide; CPI, composite physiologic index; PaO2, arterial pressure of oxygen; SpO2, percutaneous oxygen saturation; KL-6, Krebs von den Lungen-6; SP-D, surfactant protein-D; LDH, lactate dehydrogenase; CPFE, combined pulmonary fibrosis and emphysema
  3. *P < 0.01 compared with controls (Mann–Whitney U test)